Results 51 to 60 of about 22,676 (187)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts [PDF]

, 2017
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
AM Zeidan, AO Soriano, BD Cheson, BD Cheson, CJ Clopper, D Merkel, DJ DeAngelo, E Raffoux, G Garcia-Manero, G Garcia-Manero, G Garcia-Manero, H Dombret, H Khan, J Babb, JP Issa, JP Issa, JP Laubach, L Maurillo, L Pleyer, M Kirschbaum, M Lubbert, Mikkael A. Sekeres, P Atadja, P Fenaux, P Fenaux, P Maslak, P Tan, PG Richardson, SD Gore, SD Nimer, T Prebet, TE Fandy, W Blum, W Fiskus, Y Ofran, YG Lee   +35 more
core   +2 more sources

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)

Global & Regional Health Technology Assessment, 2017
IntroductionMyelodysplastic syndrome (MDS) comprises a group of clonal hematological disorders, characterized by ineffective hematopoiesis and progressive bone marrow failure.
Myrna Candelaria-Hernández, Xavier López Karpovitch, Francisco Javier Mijangos, Efreen Montaño, Arely Lemus Carmona, Silvia Guzmán Vázquez, Herman Soto Molina   +6 more
doaj   +1 more source

Epigenetics in diagnosis, prognostic assessment and treatment of cancer:An update [PDF]

, 2014
Cancer cells contain multiple genetic and epigenetic changes. The relative specificity of many epigenetic changes for neoplastic cells has allowed the identification of diagnostic, prognostic and predictive biomarkers for a number of solid tumors and ...
Briasoulis, Evangelos, Crook, Tim, Hatzimichael, Eleftheria, Lagos, Konstantinos, Sim, Van Ren   +4 more
core   +4 more sources

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Advanced Science, EarlyView.
The authors engineer colorectal cancer cells with reduced redundancy of UHRF1 and DNMT1, key DNA methylation maintenance factors, lowering the maintenance threshold and sensitizing cells to inhibition. They develop reporter assays driven by endogenous tumor‐suppressor gene promoters with enhanced sensitivity and dynamic range to demethylating drugs ...
Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong   +15 more
wiley   +1 more source

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.

PLoS ONE, 2020
Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten ...
Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher, Eric Delabesse   +15 more
doaj   +2 more sources

Effects of Cyclosporine and Azacitidine on Some Hematologic and ‎Biochemical Parameters of Benzene-Induced Aplastic Anemia in Rats

The Iraqi Journal of Veterinary Medicine, 2023
Aplastic anemia, marked by deficiencies in hematopoietic stem cells, leads to peripheral blood pancytopenia and hypocellular bone ‎marrow. This study aimed to evaluate the therapeutic efficacy of cyclosporine and azacitidine, administered either ...
ghanem taher, Huda F Hasn
doaj   +1 more source

Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy

Advanced Science, EarlyView.
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu, Jia Song Deon Chon, Yuxiao Feng, Kang Liang, Shiming Li, Can Yang Zhang, Jun Ge   +6 more
wiley   +1 more source

Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet’s-like disease accompanied with myelodysplastic syndrome involving trisomy 8

Immunological Medicine, 2019
Myelodysplastic syndromes (MDSs) are a group of myeloid neoplasms characterized by blood cell deformation and dysfunction, and MDS with trisomy 8 is closely linked with intestinal Behçet’s-like diseases.
Nahoko Tanaka, Hirotake Sakuraba, Hiroto Hiraga, Ko Mayama, Hidezumi Kikuchi, Dai Kishida, Yui Akemoto, Keisuke Hasui, Shinji Ota, Rina Watanabe, Yasuhisa Murai, Takato Maeda, Kosuke Kamata, Tetsuya Tatsuta, Manabu Sawaya, Daisuke Chinda, Tatsuya Mikami, Kazufumi Yamagata, Yoh Ishiguro, Masanori Tanaka, Shinsaku Fukuda   +20 more
doaj   +1 more source

The blind men and the AML elephant:can we feel the progress? [PDF]

, 2016
The pharmacological therapy of non-promyelocytic acute myeloid leukemia (AML) has remained unchanged for over 40 years with an anthracycline–cytarabine combination forming the backbone of induction treatments.
A Wanquet, AK Burnett, AK Burnett, AK Burnett, AK Burnett, AK Burnett, AK Burnett, AM Perry, D Garfield, DW Milligan, EL Korn, Experts in Chronic Myeloid Leukemia, F Ravandi, F Ravandi, F Turturro, H Dombret, HF Fernandez, I Gojo, J Loke, K Wheatley, K Wheatley, LR Silverman, M Lübbert, M Weil, MR Luskin, MW Drummond, NI Cherny, P Fenaux, P Greenberg, P Paschka, PB Bach, PF Bross, RC Young, RK Hills, S Amadori, S Castaigne, SH Petersdorf, SY Zafar, ZY Wang   +38 more
core   +3 more sources